Stay updated on Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial

Sign up to get notified when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Site revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-17T02:31:39.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    Added two study record dates (2026-04-07 and 2026-04-08) and removed two earlier dates (2026-04-01 and 2026-03-31) from the Study Record Dates.
    Difference
    0.2%
    Check dated 2026-04-09T21:01:00.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    Two new update dates (2026-04-01 and 2026-03-31) were added to the study record history, and two older dates (2026-03-06 and 2026-03-05) were removed.
    Difference
    0.2%
    Check dated 2026-04-02T15:24:38.000Z thumbnail image
  4. Check
    35 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.3 to v3.5.0 on the page.
    Difference
    0.1%
    Check dated 2026-03-19T05:57:57.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Added revision notes for v3.4.3 on 2026-03-05 and 2026-03-06; older revision v3.4.2 is listed under deletions.
    Difference
    0.3%
    Check dated 2026-03-12T02:22:02.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    New update entries were added for 2026-02-20, 2026-02-21, and 2026-02-24. Older update entries for 2026-02-14, 2026-02-17, and 2025-11-28 were removed.
    Difference
    0.3%
    Check dated 2026-02-25T18:54:02.000Z thumbnail image

Stay in the know with updates to Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.